Manage Account
Change Password
Sign Out
UserName
Profession Email
Profession Email
|
Contraindications
Hypersensitivity. Severe myelosuppression (e.g. leucopenia and/or thrombocytopenia). Severe hepatic or renal impairment. Pregnancy and lactation.
|
|
Special Precautions
Hepatic and renal impairment. Patient Counselling May impair ability to drive or operate machinery. Monitoring Parameters Monitor CBC w/ differential, leukocyte, erythrocyte and platelet count, LFT; infusion site for extravasation. Assess signs of infection and hepatotoxicity.
|
|
Adverse Reactions
Anorexia, vomiting, nausea, rash, alopecia, facial flushing and paraesthesia, orthostatic hypotension, ECG abnormalities, flu-like syndrome, myalgia, malaise, blurred vision, seizure, headache, confusion, lethargy, pain at inj site, tissue damage, cellulitis. Rarely, diarrhoea, photosensitivity, stomatitis.
Potentially Fatal: Anaphylaxis, bone marrow suppression (particularly leucopenia and thrombocytopenia), hepatotoxicity accompanied by hepatic vein thrombosis and hepatocellular necrosis. |
|
Drug Interactions
Increased metabolism when used w/ enzyme inducers (e.g. barbiturates, rifampicin, phenytoin). May potentiate the effect of mercaptopurine, azathioprine, allopurinol. May impair immune response to vaccines. May enhance the effects of methoxsalen due to photosensitisation.
|
|
CIMS Class
|
|
ATC Classification
L01AX04 - dacarbazine ; Belongs to the class of other alkylating agents. Used in the treatment of cancer.
|
